Clinical Oncology: Case ReportsJournal of Oncology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Impressive Response to Immunotherapy in a Patient with Metastatic Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare cancer with limited effective treatment options and poor prognosis. ACC incidence is 1 to 2 cases per million making randomized clinical trials difficult to conduct. The current standard first line treatment for metastatic ACC showing tumor response and improved progression free survival (PFS) is etoposide-doxorubicin-cisplatin (EDP) plus mitotane. Multiple efforts to find a targeted treatment for ACC have not shown impressive responses. Immunotherapy agents such as checkpoint inhibitors programmed cell death – 1 receptor (PD-1) and programmed cell deathligand 1 have shown significant responses in multiple malignancies including melanoma, non-small-cell-lung cancer, Hodgkin’s lymphoma to name a few. We present a case of a female patient with metastatic ACC involving the lungs, lymph nodes, and liver who progressed after EDP-mitotane, then had a significant decrease in tumor burden with anti-PD-1 agent pembrolizuamb.

Special Features

Full Text


Track Your Manuscript

Media Partners